Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal

Kogielem Naidoo,1,2 Navisha Dookie,1,3 Kasavan Naidoo,2 Nonhlanhla Yende-Zuma,1 Benjamin Chimukangara,1,3,4 Ambika Bhushan,1 Dhineshree Govender,1 Santhanakshmi Gengiah,1 Nesri Padayatchi1,2

1Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; 2South African Medical Research Council (SAMRC) - CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa; 3KwaZulu Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa; 4Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, Durban, South Africa

Background: Recurrent tuberculosis (TB) following TB treatment completion in HIV-infected individuals remains a major public health burden. We assessed the role of various risk factors in mediating the development of recurrent TB and subsequent resistance to antiretroviral therapy and anti-TB drugs.

Patients and methods: We analyzed secondary demographic, clinical, and laboratory data from medical records of five HIV-infected TB patients enrolled between 2009 and 2014 in a prospective observational study investigating TB recurrence. Paired clinical isolates of Mycobacterium tuberculosis were typed by IS6110 restriction fragment length polymorphism analysis to determine the mechanism of TB recurrence. Plasma samples were genotyped to determine acquisition of HIV drug resistance mutations on antiretroviral treatment (ART).

Results: All five patients were HIV-coinfected, with a previous history of TB infection and prior exposure to anti-TB treatment, and residual lung damage, and demonstrated poor treatment adherence – significant risk factors linked to the development of recurrent TB disease. Furthermore, three of the five patients had multiple episodes of drug-susceptible TB infection with subsequent drug-resistant TB infection. Genotyping of the initial and recurrent M. tuberculosis isolates demonstrated three cases of recurrent TB because of relapse and two because of reinfection. All five patients had no mutations at ART initiation; however, by the end of the study follow-up, all patients developed dual class resistance.

Conclusion: This series demonstrates the complexity of recurrent TB in HIV coinfection. We highlight the challenges of managing coinfected patients and the increased propensity for the development of drug resistance. We report on the role of various risk factors mediating the development of resistance and subsequent clinical impact. This report underscores the need for structural clinical and adherence interventions for the management of complex treatment and dosing.

Keywords: adherence, TB–HIV coinfection, social risk factors, IS6110 RFLP, drug resistance

Introduction

Globally, tuberculosis (TB) presents as the most common opportunistic infection in people with HIV.1 In the latest global TB report, the World Health Organization estimated that 10% of the 10.4 million incident cases of TB in 2016 were coinfected with HIV. Sub-Saharan Africa bears the highest rates of HIV-associated TB, with coinfection rates of up to 50% in some areas.1 In HIV-uninfected individuals with latent TB infection, the lifetime risk of TB reactivation disease is 10%. This risk is increased to 10% per annum in HIV-infected patients.2 In addition to the increased risk of TB reactivation, HIV coinfection has also been reported as a significant risk...
factor for recurrent TB disease. Weakened immune responses, a hallmark characteristic of HIV infection, facilitates the progression to active TB disease and is a significant risk factor for recurrent TB disease.1-3 HIV–TB coinfection is further complicated by the development of drug resistance in *Mycobacterium tuberculosis*.4-6

Recurrent TB disease, following cure or successful treatment completion, occurs as a result of either relapse (reurrence of the previous infection) or reinfection (infection with a new strain type), each associated with its own risk factors. Risk factors associated with individual vulnerability including immune compromise due to comorbidities such as HIV coinfection and diabetes mellitus, residual lung damage due to previous TB infection, age, malnutrition, and social risk factors such as alcohol abuse and cigarette smoking have been attributed to both relapse and reinfection. Risk factors that impact on treatment response such as inadequate treatment regimen, poor treatment adherence, and unrecognized drug resistance or host-specific factors that affect drug metabolism have been attributed to relapse of TB disease. Increased risk due to poor epidemic or infection control resulting in repeat exposure has been attributed to reinfection. Distinguishing between relapse and reinfection requires comparing the homology of *M. tuberculosis* strains isolated during the first and recurrent TB episodes using molecular-based DNA fingerprinting techniques.7,8

Complex multi-drug regimens and optimal medication adherence are required for effective treatment of TB/HIV coinfection.9-11 This results in challenges of adherence to complex dosing strategies, long duration of therapy, serious and often life-threatening drug side effects, and drug–drug interactions.11 Adherence, a major factor undermining treatment outcomes, relies on patients’ attitude, knowledge, and beliefs, which are in turn influenced by poverty, gender, stigma, and other social and cultural factors.9,14 Patients failing TB treatment are likely to remain infectious thereby increasing the likelihood of ongoing transmission of infection.9,15,16 We report and analyze five patients with HIV–TB coinfection, receiving concomitant treatment for both diseases and who subsequently developed recurrent drug-resistant TB (DR-TB). This report highlights the various risk factors that contributed to the development of recurrent TB.

### Patients and methods

We conducted a retrospective chart review on a subset of patients enrolled in the CAPRISA TRuTH study investigating the incidence of TB recurrence in adult TB/HIV-coinfected patients, who previously completed treatment for drug-sensitive pulmonary TB in the CAPRISA SAPiT trial.17 The study was conducted between June 2005 and August 2013. Patients were followed up quarterly for 5 years. Among 82 patients who developed recurrent TB, five patients were diagnosed with recurrent DR-TB. Case notes were used to report the contributing risk factors to the development of recurrent TB.

Patients diagnosed were treated with standard TB treatment, and treatment outcomes were recorded as per the South African National TB control program guidelines.18 Patients were initiated on a once-daily first-line antiretroviral treatment (ART) regimen and managed as per national guidelines.19 Participants received TB treatment adherence – counseling occurred prior to TB treatment initiation, and adherence was enhanced and verified through TB directly observed therapy short-course (DOTS) program. ART adherence support occurred through group counseling, two sessions prior to initiation, one on the day of treatment, and continued six-monthly thereafter. Adherence was assessed by clinic-based pill count at all scheduled visits, and six-monthly virologic outcomes. Adherence was described according to previously published categories by medication possession ratios and patient self-reporting.

To determine the mechanism mediating TB recurrence, initial and recurrent isolates were genotyped using the IS6110 restriction fragment length polymorphism method.22,23 To assess the impact of HIV on TB recurrence, HIV virologic markers were assessed and stored plasma samples were analyzed for drug resistance conferring mutations prior to ART initiation, at the entry of the TRuTH study, and at the end of the study. HIV drug resistance sequencing incorporated the viral protease (codons 1–99) and reverse transcriptase (codons 1–230) genes. Drug resistance mutations were interpreted using the Stanford University HIV drug resistance database16,19 and the International AIDS Society mutation list.19

Ethical approval for the TRuTH study was obtained from the University of KwaZulu-Natal Biomedical Ethics Research Committee, reference number BF051/09; Clinical trials number NCT01539005. Written informed consent was obtained from all participants to publish case details and images with no personal identifiers.

### Results

In-depth clinical profiles for each patient are described in Table 1. The mean age was 34.8 (range, 30–38) years during the first TB episode. Among the five participants, two were female and three were male. One patient displayed a body mass index (BMI) of 17.0, falling within the underweight


<table>
<thead>
<tr>
<th>Clinical and epidemiologic biomarker</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>38</td>
<td>32</td>
<td>38</td>
<td>36</td>
<td>30</td>
</tr>
<tr>
<td>Gender</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>BMI at TB-1 diagnosis</td>
<td>19.4</td>
<td>18.7</td>
<td>17.6</td>
<td>21.4</td>
<td>26</td>
</tr>
<tr>
<td>BMI at TB-1 end</td>
<td>18.4</td>
<td>20.5</td>
<td>18.7</td>
<td>23.2</td>
<td>26.5</td>
</tr>
<tr>
<td>BMI at TB-2 diagnosis</td>
<td>21.3</td>
<td>20.4</td>
<td>17.0</td>
<td>19.4</td>
<td>25.8</td>
</tr>
<tr>
<td>Genetic and susceptibility profile</td>
<td>Beijing</td>
<td>F15/LAM4/KZN</td>
<td>F28</td>
<td>F28</td>
<td>Unique</td>
</tr>
<tr>
<td>Chest radiograph</td>
<td>Infiltrates on RL; cavities and infiltrates on LL</td>
<td>Infiltrates on RL and LL</td>
<td>Cavities, infiltrates, pleural disease, and shrinkage and destruction in RL, minimal fibrosis on LL</td>
<td>Cavities and infiltrates in RL and LL</td>
<td>Cavities and infiltrates in RL and LL</td>
</tr>
<tr>
<td>Completion date, duration on treatment and outcome</td>
<td>1 April 2008</td>
<td>20 March 2008</td>
<td>20 August 2007</td>
<td>Jun 30 2008</td>
<td>02 January 06</td>
</tr>
<tr>
<td></td>
<td>8 months</td>
<td>8 months</td>
<td>10 months</td>
<td>7 months</td>
<td>6 months</td>
</tr>
<tr>
<td></td>
<td>Cure</td>
<td>Cure</td>
<td>Cure</td>
<td>Cure</td>
<td>Cure</td>
</tr>
<tr>
<td>Chest radiograph at the end of treatment</td>
<td>Fibrosis in upper RL</td>
<td>Fibrosis in LL</td>
<td>Extensive fibrosis</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td>Recurrent MDR/XDR episode of TB</td>
<td>Reinfection</td>
<td>Relapse</td>
<td>Reinfection</td>
<td>Relapse</td>
<td>Relapse</td>
</tr>
<tr>
<td>Mechanism of recurrence, genetic profile of TB isolates and time to recurrence</td>
<td>Beijing to KZN strain</td>
<td>Beijing to KZN strain</td>
<td>F28 – unique</td>
<td>F28 strain</td>
<td>Unique strain</td>
</tr>
<tr>
<td></td>
<td>24 months</td>
<td>28 months</td>
<td>19 months</td>
<td>28 months</td>
<td>15 months</td>
</tr>
<tr>
<td>Date and method of diagnosis</td>
<td>June 10</td>
<td>Feb 2011</td>
<td>Apr 2010</td>
<td>Nov 2010</td>
<td>May 07</td>
</tr>
<tr>
<td>Susceptibility profile</td>
<td>XDR-TB</td>
<td>MDR-TB</td>
<td>MDR-TB</td>
<td>MDR-TB</td>
<td>XDR-TB</td>
</tr>
<tr>
<td></td>
<td>Resist to INH, RIF, EM, kanamycin, capreomycin, OFX, lialamide, SM, ETH, and PZA</td>
<td>Resist to INH, RIF, ETH, SM, and PZA</td>
<td>Resist to INH, RIF, ETH, SM, and PZA</td>
<td>Resist to INH, RIF, ETH, SM, and PZA</td>
<td>Resist to INH, RIF, ETH, SM, and PZA</td>
</tr>
<tr>
<td>Radiologic findings</td>
<td>Infiltrates on RL and infiltrates and new lesions on LL</td>
<td>Caviities in LL</td>
<td>Bullae and plural effusion in RL</td>
<td>Caviities and infiltrates on RL and fibrosis on LL</td>
<td>Cavitation in LL</td>
</tr>
<tr>
<td>Treatment outcome</td>
<td>Transferred out for DR-TB care</td>
<td>Transferred out for DR-TB care</td>
<td>Died</td>
<td>Withdrew from study</td>
<td>Transferred out for DR-TB care</td>
</tr>
<tr>
<td>HIV history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment regimen</td>
<td>AZT/3TC/EFV, switched AZT to TDF in May 2009</td>
<td>ddl/3TC/EFV (discontinued between March and April 2009)</td>
<td>ddl/3TC/EFV</td>
<td>ddl/3TC/EFV switched to ABC/ TDF/LP/vr in October 2008, and back to regimen 1 in June 2011</td>
<td>ddl/3TC/EFV switched to TDF in July 2011</td>
</tr>
</tbody>
</table>

(Continued)
range during the recurrent TB episode. The remaining patients recorded BMI values in the normal range.

**TB history and associated risk factors for recurrent TB**

All five patients had a previous history of TB disease for which they received between 6 and 10 months of DS anti-TB treatment, before enrolling into the TRuTH study. Patients 1 and 5 subsequently developed XDR-TB, and the remaining patients developed MDR-TB. Patients 1, 2, and 3 presented with DR-TB in the TRuTH study 24, 28, and 19 months, respectively, after successful treatment completion for two prior episodes of DS-TB. Patients 4 and 5 presented with DR-TB during the TRuTH study 28 and 15 months, respectively, after successful treatment completion for one episode of DS-TB. Assessment of radiographic chest X-rays during initial TB infection, point of cure for initial TB episode, and TB relapse (Figures S1–S4 and Table 1) indicated that recurrent TB infection was characterized by the presence of vast damage to the lungs and residual damage from prior TB infection. Month 2 sputum culture results were only available for patients 1 and 2, both of which remained positive. The remaining patients had only sputum smear results available, all of which were negative. Among the paired M. tuberculosis isolates representing the initial and recurrent TB episodes, there were two cases of TB reinfection (patients 1 and 3) and three cases of TB relapse (patients 2, 4, and 5). Detailed data on genetic profiles, drug susceptibility profiles, and timelines for recurrent disease episodes are reported in Table 1.

**HIV coinfection and its impact on recurrent TB disease**

All five patients were diagnosed with HIV at screening of the SAPiT trial and initiated on standard treatment at various points during concomitant anti-TB therapy. The mean CD4+ T cell count was 171 cells/mm³ at diagnosis of the initial TB episode, 341.2 cells/mm³ at cure of the first TB episode and 289 cells/mm³ at diagnosis of recurrent TB. CD4 and viral load data for each patient are detailed in Table 1. Retrospective analysis of HIV drug resistance mutations demonstrated that the patients had no pre-ART drug resistance mutations. However, over the course of treatment and

<table>
<thead>
<tr>
<th>Clinical and epidemiologic biomarker</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient case 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regimen response</td>
<td>Virologic suppression; sustained high</td>
<td>Raised CD4 count and virologic suppression by</td>
<td>Good virologic suppression, CD4 cell count remained low</td>
<td>Failed both regimens, placed back onto Regimen</td>
<td>Good virologic suppression, CD4 count remained low</td>
</tr>
<tr>
<td>CD4/VL at initial TB diagnosis</td>
<td>CD4 =200</td>
<td>CD4 =54</td>
<td>CD4 =151</td>
<td>CD4 =245</td>
<td>CD4 =205</td>
</tr>
<tr>
<td>CD4/VL at the end of first TB episode</td>
<td>VL =260,000</td>
<td>VL =126,000</td>
<td>VL =41,663</td>
<td>VL = Unavailable</td>
<td>VL =83,900</td>
</tr>
<tr>
<td>CD4/VL at recurrent TB diagnosis</td>
<td>CD4 =434</td>
<td>CD4 =377</td>
<td>CD4 =331</td>
<td>CD4 =212</td>
<td>CD4 =352</td>
</tr>
<tr>
<td>Other notes</td>
<td>Hospitalization</td>
<td>Hospitalization</td>
<td>Hospitalization</td>
<td>Household TB contacts</td>
<td>No risks</td>
</tr>
<tr>
<td>Adherence profile</td>
<td>Poor; adherence support program</td>
<td>Fair; missed clinic visits due to alcohol use, occasional missing of doses</td>
<td>Good</td>
<td>Poor; hospitalization for supervised TB treatment</td>
<td>Good</td>
</tr>
<tr>
<td>Other medical conditions</td>
<td>Anemia, PN, SN, HepB</td>
<td>IRIS on TB treatment, PN</td>
<td>PN, pneumonia in August 2010</td>
<td>Hypertension, PN</td>
<td>None</td>
</tr>
<tr>
<td>Substance use history</td>
<td>Alcohol abuse, smoking</td>
<td>Alcohol abuse, smoking</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

**Notes:** Initial episode of TB = TB-1; Recurrent episode of TB = TB-2; radiological findings from chest X-rays conducted after diagnosis and treatment end (closest date available given).

**Abbreviations:** 3TC, lamivudine; ABC, abacavir; ALV, alvocidib; AZT, azidothymidine; BMI, body mass index; CD4, CD4+ T-cell count (cells/µL); DDI, didanosine; EFV, efavirenz; EMB, ethambutol; ETH, ethionamide; Hep B, hepatitis B; INH, isoniazid; LL, left lung; MDR, multi-drug-resistant; OFX, ofloxacin; PN, peripheral neuropathy; PTB, pulmonary TB; PZA, pyrazinamide; R4, Rifafour; RIF, rifampicin; RL, right lung; SM, streptomycin; SN, sensory neuropathy; TB, tuberculosis; TDF, tenofovir; VL, viral load (copies/µL); XDR, extensively drug-resistant.
Adherence and social risk factors

There were various social risk factors and treatment adherence issues that played a role in the complex clinical course of these patients. Patient 1 had a history of alcohol abuse resulting in poor adherence, missed clinic visits, and discontinuation of ART for a period of 6 months. The patient’s hospital admission also coincided with diagnosis of his recurrent TB episode. Patient 2 also had a reported history of alcohol abuse resulting in poor adherence and incarceration that coincided with his MDR-TB diagnosis. Patient 3 reported that her partner was HIV positive who was not on ART and declined condom use with her. In addition, this patient reported a low level of educational attainment. Patient 4 displayed poor adherence despite receiving intensive counseling under study conditions. She also reported close contacts with TB patients, no condom use, and low level of educational attainment. Patient 5 reported no significant adherence or social risk factors.

Discussion

This series highlights the impact of various risk factors in the development of recurrent TB infection in five HIV-coinfected patients. We further highlight the considerable complexity in the management of coinfected patients because of the use of multiple drugs with complex dosing schedules, and prolonged treatment course that is often complicated by severe overlapping drug toxicities. Published data from various settings consistently demonstrate the impact of these factors on patient adherence and retention in care.

Notwithstanding the small sample size in this case series, the following important findings should be noted. All five patients were HIV coinfected with a previous history of TB infection and prior exposure to anti-TB treatment, residual lung damage, and demonstration of poor treatment adherence; significant risk factors linked to the development of recurrent TB disease. Furthermore, three of the five patients had multiple episodes of DS-TB infection with subsequent DR-TB infection. Strain typing revealed that recurrence occurred by relapse in three cases and by reinfecion in two cases. While published reports attribute reinfection as the main mechanism of recurrence in the context of HIV coinfection, we demonstrated three cases of relapse in our study among HIV/TB-coinfected patients. Furthermore, our data support findings of a recent South African study showing ongoing transmission of DR-TB, and the low rates of TB culture conversion including frequent reversion.

We retrospectively analyzed the development of ART resistance mutations in our recurrent TB patients. Despite having no mutations at ART initiation, by the end of the study all five patients developed dual class resistance with NNRTI mutations featuring prominently. The considerable pill burden imposed by the addition of DR-TB treatment to chronic ART is likely to have negatively impacted ART adherence fueling development of ART resistance. These findings are consistent with the published surveillance studies conducted in this setting, reporting the mutations detected in this study as prevalent mutations associated with acquired resistance in adults. Retrospective analysis of the resistance mutations reveals that patients were receiving inadequate ART for optimal viral suppression. Furthermore, guidelines advocate first-line ART regimen switch without the benefit of ART resistance testing. This coupled with the lack of objective markers of ART adherence comprises early detection and management of ART failure. Most importantly, these cases highlight the need for ongoing clinical monitoring for treatment failure and HIV resistance testing, especially in patients taking complex regimen for multiple concurrent conditions.

Suboptimal adherence to treatment was a key factor driving drug resistance in this subset of patients. Despite receiving enhanced counseling support under clinical trial conditions, patients remained nonadherent. In keeping with previous reports, known behavioral and biologic risk factors such as alcohol misuse, incarceration, hospital admission, poor pill-taking behavior, low level of education attainment, and missed clinic appointments featured among patients failing treatment and acquiring resistance in this study. Despite access to free care for both HIV and TB, underlying social issues severely impacted treatment outcomes underscoring the need for strong ongoing support directed at optimizing treatment adherence and treatment completion. DOTS programs played a pivotal role in increasing treatment completion rates globally. Adopting a similar strategy for the management of DR-TB and HIV coinfection could impact on reducing recurrent TB rates. As reinfection rates are higher in HIV endemic settings like South Africa, we also highlight the need for enhanced infection control measures...
and ongoing surveillance in congregate settings such as clinic waiting rooms, hospitals, and prisons.43,44

We would like to acknowledge study limitations. Secondary study data and stored samples from the study biorepository were analyzed. We had to rely on self-reported information regarding prior ARV treatment and ART and TB adherence. The lack of availability of objective markers of adherence undermines our ability to understand the evolution of drug resistance to ART and TB drugs. Furthermore, the small sample size limits the generalizability of our findings to other patients and settings. We also did not establish if these patients had mixed strain infection and the extent to which this might have influenced our findings.

In conclusion, the cases described in this series highlight the public health crisis resulting from the intersecting epidemics of DR-TB and drug-resistant HIV. The study underscores the complexity of managing TB and HIV coinfection, and the impact of various risk factors in mediating resistance. Patients failing treatment present a public health risk of ongoing transmission of resistant strains. Distinguishing between relapse and reinfection plays an invaluable role in addressing the burden of recurrent TB disease. High rates of relapse underscore the need for renewed interventions to improve individual patient care while high rates of reinfection underscore the need for improved epidemic control measures. Urgent attention is also required to address challenges of adherence, such as social and health care worker support systems and step-down management facilities. Enhanced treatment options, such as intensified initial treatment, extension of treatment, and preventative therapy for patients presenting with multiple risk factors, will prevent recurrent TB infection. The heightened risk of recurrent TB in ART programs underscores the need for regular TB screening at ART follow-up visits. There has been considerable disparity in the studies reporting on the role of relapse vs reinfection. Further large-scale studies are required to address the role of relapse and reinfection as well as the role of mixed infections in recurrent TB.

Acknowledgments

The authors would like to thank the CAPRISA clinic team and participants of the SAPiT and TRuTH studies at the eThekwini Clinic.

This study was supported by the US President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to fight AIDS, Tuberculosis and Malaria and the National Institutes of Health Comprehensive International Program of Research on AIDS. KN and NP were supported by the Columbia University-South Africa Fogarty AIDS International Training and Research Program (AITRP, Grant D43 TW000231).

Disclosure

The authors report no conflicts of interest in this work.

References


Supplementary materials

Chest radiographs for Patients 1–4 (no images available for Patient 5).

**Figure S1** Chest X-rays of Patient 1 depicting (A) infiltrates on both lungs; (B) persistent fibrosis in the left lung; and (C) cavities in the left lung.

**Figure S2** Chest X-rays of Patient 2 depicting (A) infiltrates in both lungs and cavities in the left lung; (B) right upper lobe fibrosis; and (C) infiltrates in the right lung and infiltrates and new lesions in the left lung.

**Figure S3** Chest X-rays of Patient 3 depicting (A) cavities and infiltrates in both lungs; (B) cavities and infiltrates on the right lung and fibrosis in the left lung; and (C) cavities, infiltrates, and patchy consolidation in the right lung and consolidation in mid and lower zones of the left lung.

**Figure S4** Chest X-rays of Patient 4 depicting (A) vast damage to the right lung with cavities, infiltrates, pleural disease, shrinkage, and destruction. Minimal damage to the left lung; (B) residual widespread damage to the right lung; and (C) right lung bullae and new pleural effusion. New infiltrates in left lung.